XOFIGO Drug Patent Profile

When do Xofigo patents expire, and what generic alternatives are available?

Xofigo is a drug marketed by Bayer Hlthcare and is included in one NDA.

The generic ingredient in XOFIGO is radium ra-223 dichloride. One supplier is listed for this compound. Additional details are available on the radium ra-223 dichloride profile page.

Summary for XOFIGO

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	30
Drug Prices:	Drug price information for XOFIGO
What excipients (inactive ingredients) are in XOFIGO?	XOFIGO excipients list
DailyMed Link:	XOFIGO at DailyMed

See drug prices for XOFIGO

Recent Clinical Trials for XOFIGO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
GenesisCare USA	Phase 3
Bayer	Phase 4
Bayer	Phase 3

See all XOFIGO clinical trials

Pharmacology for XOFIGO

Drug Class	Radioactive alpha-Particle Emitting Therapeutic Agent
Mechanism of Action	alpha-Particle Emitting Activity

US Patents and Regulatory Information for XOFIGO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Hlthcare	XOFIGO	radium ra-223 dichloride	SOLUTION;INTRAVENOUS	203971-001	May 15, 2013		RX	Yes	Yes

Expired US Patents for XOFIGO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Hlthcare	XOFIGO	radium ra-223 dichloride	SOLUTION;INTRAVENOUS	203971-001	May 15, 2013	6,635,234

International Patents for XOFIGO

See the table below for patents covering XOFIGO around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	1140212	UTILISATION DU RADIUM 223 POUR CIBLER DES TISSUS CALCIFIES A DES FINS DE TRAITEMENT PALLIATIF ET TRAITEMENT CONTRE LA DOULEUR DU CANCER DES OS (THE USE OF RADIUM-223 TO TARGET CALCIFIED TISSUES FOR PAIN PALLIATION AND THERAPY OF BONE CANCER)
Japan	4649044
New Zealand	545023	Preparation comprising dissolved radium-223
Austria	331534
Luxembourg	92425
Denmark	1140212
Norway	310544

Supplementary Protection Certificates for XOFIGO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1140212	C300666	Netherlands		PRODUCT NAME: RADIUM-223, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH; REGISTRATION NO/DATE: EU/1/13/873/001 20131113
1140212	2014/033	Ireland		PRODUCT NAME: RADIUM-223 AND SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/873 20131113
1140212	CR 2014 00027	Denmark		PRODUCT NAME: RADIUM-223 OG OPLOESELIGE SALTE DERAF, HERUNDER RADIUM-223 DICHLORID; REG. NO/DATE: EU/1/13/873 20131113
1140212	122014000052	Germany		PRODUCT NAME: RADIUM-223-SALZ, INSBESONDERE RADIUM-223-DICHLORID; REGISTRATION NO/DATE: EU/1/13/873 20131113
1140212	507	Finland
1140212	33/2014	Austria		PRODUCT NAME: RADIUM-223-DICHLORID; REGISTRATION NO/DATE: EU/1/13/873 20131113
1140212	CA 2014 00027	Denmark		PRODUCT NAME: RADIUM-223 OG OPLOESELIGE SALTE DERAF, HERUNDER RADIUM-223 DICHLORID; REG. NO/DATE: EU/1/13/873 20131113

Market Dynamics and Financial Trajectory for XOFIGO (Radium-223 Dichloride)

Last updated: January 20, 2026

Summary

XOFIGO (Radium-223 Dichloride) is a targeted radiopharmaceutical indicated for the treatment of castration-resistant prostate cancer (CRPC) with symptomatic bone metastases. Since its U.S. approval in 2013, XOFIGO has become a significant player within the niche of radiopharmaceutical oncology therapies. Its market position is driven by increasing prostate cancer incidence, advancements in metastatic disease management, regulatory approvals, and evolving competitive landscapes. This report analyzes the key market drivers, revenue forecasts, competitive dynamics, regulatory environment, and future prospects shaping XOFIGO’s financial trajectory.

---

What Are the Core Market Drivers for XOFIGO?

1. Increasing Incidence of Prostate Cancer and Bone Metastases

• Global Incidence Trends: Prostate cancer accounts for approximately 1.4 million new cases annually worldwide (2020 data). The majority of advanced prostate cancer cases develop bone metastases, observed in over 80% of patients with metastatic CRPC [1].

• Demographic Factors: Aging populations in North America, Europe, and parts of Asia escalate the incidence rates. U.S. projections estimate over 250,000 new prostate cancer cases annually by 2025 [2].

• Impact on Market: Higher prevalence of bone metastases directly increases eligible patient populations for XOFIGO.

2. Evolving Treatment Paradigms for CRPC

• Shift Toward Targeted Radiopharmaceuticals: The growing adoption of targeted radioligand therapy complements existing hormonal and chemotherapy regimens.

• Clinical Evidence: The ALSYMPCA trial demonstrated a median overall survival benefit of 14.9 months versus 11.3 months for placebo, establishing XOFIGO's efficacy [3].

• Treatment Sequencing: XOFIGO is increasingly integrated into earlier lines of therapy, extending its addressable market.

3. Regulatory Approvals and Expanded Indications

• Initial Approval: U.S. FDA (2013), EU (2014), Japan (2018).

• Recent Developments: Pending or granted approvals in additional countries; potential label expansions for combination therapies.

• Reimbursement Policies: Favorable insurance coverage in developed markets promotes utilization.

4. Competitive Landscape and Market Share Dynamics

Competitor	Product Name	Mechanism	Approval Year	Market Share (2022)	Notes
Bayer	Xofigo	Radiopharmaceutical	2013	~60%	First-in-class alpha-emitter therapy
Novartis	Lutathera	Peptide receptor radionuclide therapy (PRRT)	2018	N/A	Competing radioligand in oncology
Others	Various	Chemo, hormonal agents	N/A	N/A	Lower market penetration

• XOFIGO maintains a dominant position due to early entry, established efficacy, and regulatory momentum.

---

What Is XOFIGO’s Revenue and Financial Trajectory?

1. Historical Financial Performance

Year	Global Revenue (USD millions)	Growth Rate	Key Notes
2013	$0.2	N/A	Launch year
2015	$74	+92%	Post-approval uptake
2018	$173	+35%	Growing adoption, expanding indications
2020	$250	+15%	Pandemic impact onset, steady market share
2022	~$300	+6%	Maturation, worldwide sales

Source: Company annual reports and industry estimates.

2. Revenue Forecasts (2023–2027)

Year	Projected Revenue (USD millions)	Assumptions	Comments
2023	$310–$330	Continued uptake, expanded access	Slight growth driven by geographic expansion
2024	$340–$370	Inclusion in earlier treatment lines	Increased patient eligibility
2025	$380–$410	Expanded indication approvals, improved reimbursement	Market maturation with higher utilization
2026	$420–$460	Competition intensifies, potential biosimilars	Price pressure and therapeutic competition impact revenues
2027	$440–$490	Technology advances, new combinations	Possible patchwork of competing therapies

• Compound Annual Growth Rate (CAGR): Approximately 8-10% between 2023–2027, mainly driven by geographic expansion, pipeline developments, and increased adoption.

3. Market Segments Contributing to Revenue

Segment	% of Revenue (2022)	Growth Drivers	Challenges
U.S. Market	60%	Early adoption, reimbursement, established clinical use	Pricing pressures, competition
Europe	25%	Regulatory approvals, pricing strategies	Market access hurdles
Asia-Pacific, ROW	15%	Emerging markets, increasing prostate cancer incidence	Less mature healthcare infrastructure

---

What Are the Key Market Dynamics Influencing Future Growth?

1. Policy and Reimbursement Trends

• U.S.: CMS (Centers for Medicare & Medicaid Services) favors innovative radiopharmaceuticals; coverage policies are moving toward broader inclusion.

• Europe: National health systems are integrating XOFIGO into official treatment guidelines with varying reimbursement levels.

• Emerging Markets: Rising healthcare expenditure supports future adoption, contingent on local price negotiations.

2. Technological and Therapeutic Advancements

• Combination Therapies: Trials combining XOFIGO with immunotherapies or hormonal agents (e.g., enzalutamide) could improve efficacy.

• Next-Generation Radioligands: Alternative alpha-emitting agents or improved delivery methods may challenge XOFIGO's market dominance.

• Imaging and Diagnostics: Enhanced detection of metastases supports personalized therapy, potentially expanding the eligible patient pool.

3. Competitive and Regulatory Risks

• Emerging Radiopharmaceuticals: Novartis’ Lutathera and other competitors could erode market share.

• Regulatory Delays: Pending approvals or safety concerns could impact sales trajectories.

• Reimbursement Shifts: Pricing pressures in key markets might constrain profit margins.

4. Patent and Intellectual Property Landscape

• Patent Protection: XOFIGO’s initial patent expired or is nearing expiration, opening pathways for biosimilars or generics.

• Pipeline Developments: Proprietary improvements or new indications may extend exclusivity or market differentiation.

---

How Does XOFIGO Compare With Similar Oncology Treatments?

Treatment Option	Mechanism	Indication	Market Status	Pros	Cons
XOFIGO (Radium-223)	Alpha-emitting radioligand	Bone metastatic CRPC	Approved worldwide	Improved survival, targeted therapy	Limited to bone metastases, price
Abiraterone acetate	Hormonal therapy	CRPC, metastatic prostate cancer	Widely used	Oral administration, efficacy	Drug interactions, resistance issues
Enzalutamide	Androgen receptor inhibitor	CRPC	Approved globally	Oral, effective in several lines of therapy	Seizure risk, resistance development
Sipuleucel-T	Immunotherapy	Asymptomatic or minimally symptomatic CRPC	U.S. approved	Durable responses in select patients	Costly, logistical complexity

---

Summary of Regulatory and Policy Environment

Region	Key Policies	Recent Acts/Guidelines	Impact on XOFIGO	Notable Developments
U.S.	CMS reimbursement, NDA approvals	21st Century Cures Act (2016), Cancer Moonshot	Favorable, supports innovation adoption	Recent inclusion in NCCN guidelines
EU	EMA approvals, national HTA	EMA approval in 2014	Widespread access	HTA evaluations influence pricing and reimbursement
Japan	PMDA approvals, national policies	Reimbursement incentives	Growing market penetration	KOL engagement prioritized

---

Conclusion: Strategic Outlook for Stakeholders

XOFIGO’s market trajectory is poised for continued growth driven by increasing prostate cancer burden, evolving treatment paradigms, and expanding indications. However, competitive pressures, patent expiries, and policy shifts necessitate adaptation. Pharmaceutical companies should focus on pipeline expansion — including combination therapies and new indications — while policymakers and payers must balance innovation incentives with cost containment.

---

Key Takeaways

• Market Growth: Anticipated CAGR of 8–10% between 2023–2027, driven primarily by geographical expansion and evolving treatment protocols.

• Revenue Drivers: Increasing prostate cancer cases, enhanced reimbursement policies, and expanding indications.

• Challenges: Patent expiries, emerging competitors, regulatory hurdles, and pricing pressures.

• Opportunities: Combination therapies, personalized diagnostics, and geographic market entry in emerging economies.

• Competitive Strategy: Maintain clinical trial momentum, deepen payer engagement, and explore pipeline innovations to sustain market dominance.

---

FAQs

1. How does XOFIGO compare to other radiopharmaceuticals in efficacy?
XOFIGO has demonstrated a median overall survival benefit of approximately 3.6 months over placebo in clinical trials, with a favorable safety profile. Its alpha-emitting properties provide localized, effective cancer cell destruction, distinguishing it from beta-emitting agents with broader tissue impact.

2. What are the major market barriers for XOFIGO?
Key barriers include patent expiration risks, competition from emerging radioligands and systemic therapies, high treatment costs, and regulatory delays or restrictions in certain markets.

3. Is XOFIGO being studied for indications beyond prostate cancer?
Current clinical trials are focused primarily on its approved indication for CRPC with bone metastases. Future off-label or expanded use depends on ongoing research into its applicability in other metastatic or radioligand therapy contexts.

4. How do reimbursement policies influence the growth of XOFIGO?
Favorable reimbursement in key markets like the U.S. and Europe facilitates patient access, directly impacting sales growth. Conversely, restrictive or uncertain reimbursement can slow adoption and limit revenue.

5. What future innovations could impact XOFIGO’s market share?
Developments such as next-generation alpha emitters, improved delivery mechanisms, combination regimens (e.g., with immunotherapy), and personalized imaging diagnostics could enhance or threaten XOFIGO’s market position.

---

References

[1] Siegel R, et al. “Cancer statistics, 2020.” CA: A Cancer Journal for Clinicians, 2020.

[2] National Cancer Institute. “Prostate Cancer Treatment." SEER Program, 2022.

[3] Parker C, et al. “Alpha emitter radium-223 in metastatic prostate cancer.” New England Journal of Medicine, 2013.

---

Note: This analysis synthesizes publicly available data, regulatory filings, clinical trial results, and market reports. Continuous market monitoring and emerging data could influence projections.